Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis.

Trial Profile

Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Alogliptin (Primary) ; Antihyperglycaemics
  • Indications Atherosclerosis; Cardiovascular disorders; Diabetic angiopathies; Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Acronyms SPEAD-A
  • Most Recent Events

    • 25 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 01 Dec 2015 Results published in the Diabetes Care
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top